

From: [Alyson Berliner](#)
To: [Dave Brown](#)
Cc: ["Deneva Zamora"](#)
Subject: FW: ARVO late breakers
Date: Monday, March 1, 2010 2:09:00 PM
Attachments: [ARVO DRAFT VEGF Trap-EYe DME abstract 022610.doc](#)

Dave,

Any thoughts about the abstract?

Thanks,
Alyson

From: Alyson Berliner
Sent: Friday, February 26, 2010 3:54 PM
To: Dave Brown
Subject: RE: ARVO late breakers

OK. If you think it will work.... Thanks!! I guess if it doesn't, could Matt be a back up?

I am attaching a draft of the abstract. Let me know what you think. We can finalize on Monday.

Thanks and have a great weekend!
Alyson

From: Dave Brown [mailto:dmbmd@houstonretina.com]
Sent: Friday, February 26, 2010 9:59 AM
To: Alyson Berliner
Subject: Re: ARVO late breakers

Its probably fine but what is your back-up plan?

I logged in and it allows my ARVO number to be used. The check boxes that "I affirm" don't ask the previous submission question.

Its up to you.-- I'd love to present it but its remotely possible they will check after the fact.

DMB

On 2/26/10 7:52 AM, "Alyson Berliner" <Alyson.Berliner@regeneron.com> wrote:

Hi Dave! Thanks... I was looking on the ARVO website for the submission guidelines and found this statement: [Late-Breaking Abstracts may be submitted only by a First Author who did not previously submit an abstract for the 2010 ARVO Annual Meeting. \(http://www.arvo.org/eweb/dynamicpage.aspx?site=am2010&WebCode=absubmissionguide\)](#)

Do you think it's still OK if you submit? Is there any way we can find out for sure?

Thanks!
Alyson

From: Dave Brown [<mailto:dmbmd@houstonretina.com>]
Sent: Thursday, February 25, 2010 7:45 PM
To: Alyson Berliner
Subject: Re: ARVO late breakers
Importance: High

Sure-- I'm you're boy. Because I was nuked-- I'm still fair game.

DMB

On 2/25/10 4:14 PM, "Alyson Berliner" <Alyson.Berliner@regeneron.com> wrote:
Hi Dave,

How are you? Hope all is well...

We are trying to find someone interested in submitting the DA VINCI data as a late breaker to ARVO (abstract due next Wednesday). The only problem is, it has to be someone that has not submitted anything already. I know you submitted the VIEW 1 abstract, but I am not sure that counts as it wasn't accepted. If you aren't already presenting something else, would you be interested? Or maybe Matt?

Thanks,
Alyson

Alyson J Berliner, MD, PhD
Director, Clinical Sciences, Ophthalmology
Regeneron Pharmaceuticals
(914) 785-3049 (office)
(914) 815-8875 (mobile)
(914) 593-1555 (fax)
Alyson.Berliner@regeneron.com

This e-mail and any attachment hereto, is intended only for use by the addressee(s) named above and may contain legally privileged and/or confidential information. If you are not the intended recipient of this e-mail, any dissemination, distribution or copying of this email, or any attachment hereto, is strictly prohibited. If you receive this email in error please immediately notify me by return electronic mail and permanently delete this email and any attachment hereto, any copy of this e-mail and of any such attachment, and any printout thereof. Finally, please note that only authorized representatives of Regeneron Pharmaceuticals, Inc. have the power and authority to enter into business dealings with any third party.

This e-mail and any attachment hereto, is intended only for use by the addressee(s) named above and may contain legally privileged and/or confidential information. If you are not the intended recipient of this e-mail, any dissemination, distribution or copying of this email, or any attachment hereto, is strictly prohibited. If you receive this email in error please immediately notify me by return electronic mail and permanently delete this email and any attachment hereto, any copy of this e-

mail and of any such attachment, and any printout thereof. Finally, please note that only authorized representatives of Regeneron Pharmaceuticals, Inc. have the power and authority to enter into business dealings with any third party.